Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget; Nicolas Boissel; Sabina Chiaretti; Hervé Dombret; Michael Doubek; Adele Fielding; Robin Foà; Sebastian Giebel; Dieter Hoelzer; Mathilde Hunault; David I Marks; Giovanni Martinelli; Oliver Ottmann; Anita Rijneveld; Philippe Rousselot; Josep Ribera; Renato Bassan

doi:10.1182/blood.2023023568

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan

The Hull York Medical School

Research output: Contribution to journal › Review article › peer-review

Abstract

Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have identified an unmet need for guidance regarding management of adult acute lymphoblastic leukemia (ALL) from diagnosis to aftercare. The group has previously summarized their recommendations regarding diagnostic approaches, prognostic factors, and assessment of ALL. The current recommendation summarizes clinical management. It covers treatment approaches, including the use of new immunotherapies, application of minimal residual disease for treatment decisions, management of specific subgroups, and challenging treatment situations as well as late effects and supportive care. The recommendation provides guidance for physicians caring for adult patients with ALL which has to be complemented by regional expertise preferably provided by national academic study groups.

Original language	English
Pages (from-to)	1903-1930
Number of pages	28
Journal	Blood
Volume	143
Issue number	19
Early online date	2 Feb 2024
DOIs	https://doi.org/10.1182/blood.2023023568
Publication status	Published - 9 May 2024

Bibliographical note

Keywords

Humans
Adult
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
Europe
Disease Management
Neoplasm, Residual/diagnosis
Prognosis

Access to Document

10.1182/blood.2023023568

Cite this

Gökbuget, N., Boissel, N., Chiaretti, S., Dombret, H., Doubek, M., Fielding, A., Foà, R., Giebel, S., Hoelzer, D., Hunault, M., Marks, D. I., Martinelli, G., Ottmann, O., Rijneveld, A., Rousselot, P., Ribera, J., & Bassan, R. (2024). Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood, 143(19), 1903-1930. https://doi.org/10.1182/blood.2023023568

@article{7549efe96ff241d1ac295a1cb90b095f,

title = "Management of ALL in adults: 2024 ELN recommendations from a European expert panel",

abstract = "Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have identified an unmet need for guidance regarding management of adult acute lymphoblastic leukemia (ALL) from diagnosis to aftercare. The group has previously summarized their recommendations regarding diagnostic approaches, prognostic factors, and assessment of ALL. The current recommendation summarizes clinical management. It covers treatment approaches, including the use of new immunotherapies, application of minimal residual disease for treatment decisions, management of specific subgroups, and challenging treatment situations as well as late effects and supportive care. The recommendation provides guidance for physicians caring for adult patients with ALL which has to be complemented by regional expertise preferably provided by national academic study groups.",

keywords = "Humans, Adult, Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy, Europe, Disease Management, Neoplasm, Residual/diagnosis, Prognosis",

author = "Nicola G{\"o}kbuget and Nicolas Boissel and Sabina Chiaretti and Herv{\'e} Dombret and Michael Doubek and Adele Fielding and Robin Fo{\`a} and Sebastian Giebel and Dieter Hoelzer and Mathilde Hunault and Marks, {David I} and Giovanni Martinelli and Oliver Ottmann and Anita Rijneveld and Philippe Rousselot and Josep Ribera and Renato Bassan",

note = "{\textcopyright} 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.",

year = "2024",

month = may,

day = "9",

doi = "10.1182/blood.2023023568",

language = "English",

volume = "143",

pages = "1903--1930",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "19",

}

Gökbuget, N, Boissel, N, Chiaretti, S, Dombret, H, Doubek, M, Fielding, A, Foà, R, Giebel, S, Hoelzer, D, Hunault, M, Marks, DI, Martinelli, G, Ottmann, O, Rijneveld, A, Rousselot, P, Ribera, J & Bassan, R 2024, 'Management of ALL in adults: 2024 ELN recommendations from a European expert panel', Blood, vol. 143, no. 19, pp. 1903-1930. https://doi.org/10.1182/blood.2023023568

TY - JOUR

T1 - Management of ALL in adults

T2 - 2024 ELN recommendations from a European expert panel

AU - Gökbuget, Nicola

AU - Boissel, Nicolas

AU - Chiaretti, Sabina

AU - Dombret, Hervé

AU - Doubek, Michael

AU - Fielding, Adele

AU - Foà, Robin

AU - Giebel, Sebastian

AU - Hoelzer, Dieter

AU - Hunault, Mathilde

AU - Marks, David I

AU - Martinelli, Giovanni

AU - Ottmann, Oliver

AU - Rijneveld, Anita

AU - Rousselot, Philippe

AU - Ribera, Josep

AU - Bassan, Renato

PY - 2024/5/9

Y1 - 2024/5/9

N2 - Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have identified an unmet need for guidance regarding management of adult acute lymphoblastic leukemia (ALL) from diagnosis to aftercare. The group has previously summarized their recommendations regarding diagnostic approaches, prognostic factors, and assessment of ALL. The current recommendation summarizes clinical management. It covers treatment approaches, including the use of new immunotherapies, application of minimal residual disease for treatment decisions, management of specific subgroups, and challenging treatment situations as well as late effects and supportive care. The recommendation provides guidance for physicians caring for adult patients with ALL which has to be complemented by regional expertise preferably provided by national academic study groups.

AB - Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have identified an unmet need for guidance regarding management of adult acute lymphoblastic leukemia (ALL) from diagnosis to aftercare. The group has previously summarized their recommendations regarding diagnostic approaches, prognostic factors, and assessment of ALL. The current recommendation summarizes clinical management. It covers treatment approaches, including the use of new immunotherapies, application of minimal residual disease for treatment decisions, management of specific subgroups, and challenging treatment situations as well as late effects and supportive care. The recommendation provides guidance for physicians caring for adult patients with ALL which has to be complemented by regional expertise preferably provided by national academic study groups.

KW - Humans

KW - Adult

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy

KW - Europe

KW - Disease Management

KW - Neoplasm, Residual/diagnosis

KW - Prognosis

U2 - 10.1182/blood.2023023568

DO - 10.1182/blood.2023023568

M3 - Review article

C2 - 38306595

SN - 0006-4971

VL - 143

SP - 1903

EP - 1930

JO - Blood

JF - Blood

IS - 19

ER -